Contents Manufacturing
19 Sustainability in mind Reaching carbon neutrality by 2040 will require a lot more of pharmaceutical companies than reducing CO2
emissions, water and 6 News & numbers
In this issue
The vital headlines and statistics defining the industry.
Drug delivery
8 The viscosity problem It’s no surprise that the physical characteristics of an injectable substance will have a bearing on how it functions inside the body. But exactly what those effects are may not be so intuitive. Viscosity is a good example here, as it has an impact on the pressure required to push the drug through the needle and into the injection site, but can also affect the level of pain experienced by patients. Monica Karpinski speaks to experts in formulation science and injectable devices to discuss this viscosity problem, and what can be done to tackle it.
19 4
13 Going modular for faster development SHL Medical
8
16 Innovation in inhalation Blue and brown inhalers have become synonymous with asthma, but inhaling doses of medication is something we might see more of as drug developers look at inhalation as a strategy to treat more than just common respiratory diseases. Theresa Devereux speaks to Ben Forbes, professor of pharmaceutics at the Institute of Pharmaceutical Science at King’s College London; and Nélio Drumond, expert in patient-centric drug product design and associate director of manufacturing sciences at Takeda, to evaluate the state of play for inhaled drug delivery.
electricity. Coordinated effort is required across disciplines, from packaging to logistics to patient engagement. Elly Earls speaks to Iris Obermueller, Merck Healthcare’s global director of environment, health and safety, to find out why the human factor is so important to building sustainable practices, and why nothing is going to change overnight.
23 Filtration BEA Technologies
25 Fast moving technology Stäubli Robotics
Outsourcing
26 The right selection A large portion of pharmaceutical manufacturing happens outside of the premises of the companies who brand and sell drug products. According to some sources, it could be as high as two-thirds of drug production that’s outsourced. With that amount of reliance on an external partner, drug companies must be diligent when selecting the right contract manufacturer for the job. Sarah Harris asks Lloyd Mager, market solutions officer for
Trust.med, and Viraj Gandhi, CEO at Medivant Healthcare, what criteria they apply when selecting an outsourcing partner, and how they go about evaluating the process for compliance and efficiency.
29 Groundbreaking innovation in inner-surface treatment Stoelzle
31 Labelling at sub-zero temperatures Faubel Group
Chemicals & raw materials
32 Polysorbates and their alternatives
Unlike small-molecule drugs – which World Pharmaceutical Frontiers /
www.worldpharmaceuticals.net
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61
